Eosinophilic Esophagitis Market Size, Share, Treatment, Symptoms, Analysis, Segmented Overview and Outlook, Pipeline Review, H1 2016

Hexa Reports
Market Research Reports and Insightful Company Profiles
Eosinophilic Esophagitis Market Size, Share, Treatment,
Symptoms, Analysis, Segmented Overview and Outlook,
Pipeline Review, H1 2016
Global Markets Direct's, 'Eosinophilic Esophagitis - Pipeline Review, H1 2016', provides an overview of
the Eosinophilic Esophagitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Eosinophilic
Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved in therapeutic
development for Eosinophilic Esophagitis and features dormant and discontinued projects.
Browse Detail Report With TOC @ http://www.hexareports.com/report/eosinophilic-esophagitispipeline-review-h1-2016/details
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic
review following a stringent set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Hexa Reports
Market Research Reports and Insightful Company Profiles
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance
of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews pipeline therapeutics for Eosinophilic Esophagitis by companies and
universities/research institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Eosinophilic Esophagitis therapeutics and enlists all their major
and minor projects
- The report assesses Eosinophilic Esophagitis therapeutics based on drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for
Eosinophilic Esophagitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline
depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and Scope
Hexa Reports
Market Research Reports and Insightful Company Profiles
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Request A Sample copy of This Report @ http://www.hexareports.com/sample/119072
Table of Contents
Table of Content 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Eosinophilic Esophagitis Overview 6
Therapeutics Development 7
Pipeline Products for Eosinophilic Esophagitis - Overview 7
Eosinophilic Esophagitis - Therapeutics under Development by Companies 8
Eosinophilic Esophagitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Eosinophilic Esophagitis - Products under Development by Companies 12
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 13
Celgene Corporation 13
DBV Technologies S.A. 14
Dr. Falk Pharma GmbH 15
Novartis AG 16
Regeneron Pharmaceuticals, Inc. 17
Shire Plc 18
Eosinophilic Esophagitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Allergen for Milk Allergy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
budesonide - Drug Profile 30
Product Description 30
Hexa Reports
Market Research Reports and Insightful Company Profiles
Mechanism of Action 30
R&D Progress 30
budesonide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dectrekumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dupilumab - Drug Profile 36
Browse Full Report @ http://www.hexareports.com/report/eosinophilic-esophagitis-pipeline-reviewh1-2016/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: [email protected]
Our Website: http://www.hexareports.com/
Visit Our Blogs: http://hexareports.blogspot.in